Included in the formulation
АТХ:L.03.A.X Other immunostimulants
Pharmacodynamics:Immunostimulating drug of bacterial origin for topical application in otorhinolaryngology, dentistry. It is a multivalent antigenic complex, a mixture of bacterial lysates, whose composition corresponds to the pathogens most often causing inflammatory processes in the oral cavity and pharynx.
Activates phagocytosis, promotes an increase in the number of immunocompetent cells, increases the production of lysozyme and interferon, and immunoglobulin A in saliva.
Pharmacokinetics:Not studied.
Indications:Treatment and / or prevention of inflammatory and infectious diseases of the oral cavity and pharynx:
pharyngitis;
- chronic tonsillitis;
- preoperative preparation and postoperative period after tonsillectomy;
- superficial and deep periodontosis, periodontitis, stomatitis (including aphthous), glossitis;
erythematous and ulcerative gingivitis;
- Dysbacteriosis of the oral cavity;
- infection after tooth extraction, implantation of artificial dental roots;
- ulceration caused by dentures.
X.J00-J06.J02 Acute pharyngitis
X.J30-J39.J31 Chronic rhinitis, nasopharyngitis and pharyngitis
X.J30-J39.J35.0 Chronic tonsillitis
XI.K00-K14.K05 Gingivitis and periodontal disease
XI.K00-K14.K12 Stomatitis and related lesions
XIX.T80-T88.T85.7 Infection and inflammatory response due to other internal prosthetic devices, implants and transplants
XXI.Z40-Z54.Z51.4 Preparatory procedures for subsequent treatment, not elsewhere classified
Contraindications:- autoimmune diseases;
- Children's age up to 3 years;
- increased individual sensitivity to the drug or its components.
Pregnancy and lactation:Information on the use of the drug in pregnancy is not enough. Corresponding data on animal experiments and epidemiological studies are lacking.
It is not recommended to take the drug during pregnancy and lactation (breastfeeding).
FDA recommendations are not defined.
Dosing and Administration:Adults and adolescents over 14 years with acute inflammatory diseases of the oral cavity and pharynx and exacerbation of chronic diseases the drug is prescribed in a dose of 8 tablets per day. Tablets dissolve (not chewing) in the oral cavity with an interval of 1-2 hours.The average duration of treatment is 10 days.
To prevent exacerbation of chronic inflammatory diseases of the oral cavity and pharynx, the drug is prescribed in a dose of 6 tablets per day. Tablets dissolve (not chewing) in the mouth with an interval of 2 hours. The duration of the course of treatment is 20 days.
It is recommended to conduct preventive courses 3-4 times a year.
Children aged 3 to 14 years in the treatment of acute and exacerbation of chronic inflammatory diseases of the oral cavity and pharynx drug prescribed in a dose of 6 tablets per day. Tablets dissolve (not chewing) in the oral cavity with an interval of 1-2 hours. The duration of treatment for acute diseases is 10 days, for prevention of exacerbation of chronic diseases - 20 days.
The course of preventive use is recommended to be repeated 3-4 times a year.
Side effects:Allergic reactions: rarely - skin rash, hives, angioedema.
From the digestive system: rarely - nausea, vomiting, abdominal pain.
From the respiratory system: rarely - exacerbation of bronchial asthma, cough.
Dermatological reactions: very rarely erythema nodosum.
From the coagulation system of the blood: very rarely - hemorrhagic vasculitis, thrombocytopenia.
Other: rarely - fever.
Overdose:No clinical symptoms of an overdose were noted. No reports of intoxication due to drug overdose.
Interaction:Drug interaction was not observed. The drug can be used concomitantly with other medications.
Special instructions:Do not take food and water, and rinse your mouth for one hour after applying the drug, so as not to reduce the therapeutic effectiveness of the drug.
When prescribing a drug that complies with a salt-free or low-salt diet, it must be taken into account that 1 tablet of the drug contains 15 mg of sodium.
Patients with bronchial asthma who receive drugs containing bacterial lysates cause an exacerbation of the disease (attack of bronchial asthma), it is not recommended to use the drug.
Use in Pediatrics
Children aged 3 to 6 years must resolve the tablets under the mandatory supervision of adults.
Impact on the ability to drive vehicles and manage mechanisms
There is no evidence of the need for any restrictions on activities related to driving or other mechanisms during the treatment period.